1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A

Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A

SSZSE:002294
30.79
CNY
+0.89
(+2.98%)
0.57EPS
84.72P/E
52.76BMarket Cap
Oct 27Next Earn
Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A
SZSE:002294
(Shenzhen Stock Exchange)

Recent

price

30.79

P/E

ratio

84.72

div

yld

2.55%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.24
1.41
1.75
2.22
2.77
3.32
3.65
3.98
4.43
4.25
2.7
2.87
3.17
3.02
3.6
- -
- -
Revenue per Share
0.34
0.39
0.61
0.79
1
1.21
1.33
1.39
1.39
0.68
0.06
0.5
0.58
0.52
0.54
- -
- -
Basic EPS, GAAP
-0.04
0.02
0.22
0.23
0.75
0.78
1.13
1.08
0.96
1
0.72
0.66
0.34
0.15
0.5
- -
- -
Free Cash Flow per Basic Share
0.11
0.13
0.16
0.29
0.38
0.44
0.2
1.11
0.8
0.81
0.53
0.01
0.4
0.49
0.49
- -
0.5
Dividend per Share
1.78
2.04
2.49
2.99
3.61
4.39
5.12
5.79
6.37
6.2
5.27
7.21
7.12
7.19
7.81
- -
- -
Book Value per Share
1.73
1.89
2.33
2.5
2.61
3.16
3.84
4.41
4.25
4.19
3.29
5.32
5.11
4.84
5.28
- -
- -
Tangible Book Value per Share
1,044
1,046
1,048
1,046
1,042
1,046
1,050
1,045
1,049
1,052
1,014
1,067
1,098
1,116
1,114
1,115
1,114
Basic Weighted Avg Shares
1,298
1,475
1,829
2,327
2,883
3,478
3,833
4,154
4,652
4,470
2,739
3,058
3,482
3,365
4,012
- -
- -
Sales/Revenue/Turnover
30.63
30.74
39.15
40.97
40.73
41.95
41.85
39.92
36.4
19.82
13.45
18.87
18.16
19.11
19.22
- -
- -
Operating Margin (%)
20
32
41
54
63
76
113
126
167
229
246
304
320
346
376
- -
- -
Depreciation Expense
355
405
635
830
1,042
1,266
1,396
1,452
1,458
715
61
534
637
580
602
- -
- -
Net Income, GAAP
14.44
14.56
15.29
14.66
14.29
14.87
15.78
16.23
14.75
19.91
11.65
11.92
11.12
9.49
4.33
- -
- -
Effective Tax Rate (%)
27.38
27.48
34.73
35.68
36.16
36.4
36.43
34.95
31.35
16
2.22
17.45
18.3
17.24
14.99
- -
- -
Profit Margin (%)
1,458
1,496
1,828
1,786
1,737
2,250
2,682
3,143
2,761
2,312
1,027
3,391
3,108
2,498
2,912
- -
- -
Working Capital
- -
- -
- -
- -
- -
60
45
30
242
159
97
9
20
13
4
- -
- -
LT Debt
1,865
2,135
2,607
3,135
3,788
4,696
5,460
6,159
6,868
6,666
5,592
8,046
7,977
8,055
8,752
- -
- -
Total Equity
20.19
19.78
25.55
28
29
28.69
26.07
23.86
21.44
9.45
1.07
7.27
7.88
7.25
7.26
- -
- -
Return on Invested Capital (%)
20.36
19.45
25.99
28.34
29.65
29.28
27.31
25.03
22.02
10.77
1.34
7.76
7.98
7.3
7.21
- -
- -
Return on Capital (%)
20.39
20.29
26.82
28.97
30.17
30.25
28.07
25.44
22.94
10.88
1.01
7.88
7.98
7.27
7.19
- -
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'25
Jun'25
Dec'25
ST Debt
150
181
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
3
4
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,115
1,115
1,115
Market Capitalization
36,599
52,764
55,227

Working Capital

CNY

•

in mil. unless spec.
Mar'25
Jun'25
Dec'25
Total Current Assets
4,695
4,269
- -
Cash, Cash Equivalents & STI
1,863
1,247
- -
Accounts Receivable, Net
595
701
- -
Inventories
527
540
- -
Total Current Liabilities
1,110
1,272
- -
Payables & Accruals
- -
- -
- -
ST Debt
150
181
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,091
952
958
1,011
4,012
2025
1,062
1,069
- -
- -
- -
2026
- -
1,251
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.18
0.13
0.15
0.08
0.54
2025
0.18
0.15
- -
- -
- -
2026
- -
0.15
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.21
0.29
- -
0.49
2025
- -
0.5
- -
- -
- -
2026
- -
0.55
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shenzhen Salubris Pharmaceuticals Co., Ltd. operates as an integrated pharmaceutical enterprise, engaging in the comprehensive research, development, manufacturing, and commercialization of a diverse range of medical products. The company primarily concentrates on delivering solutions for chronic conditions, with a strong emphasis on cardiovascular and cerebrovascular ailments, oncology, diabetes, orthopedic disorders, anti-infective treatments, and autoimmune and neurodegenerative diseases. Its extensive product portfolio includes advanced chemical drugs and innovative biological therapeutics. Key offerings feature cardiovascular drugs such as allisartan isoproxil and related fixed-dose combinations for hypertension and heart failure, as well as bivalirudin and clopidogrel bisulfate. In the anti-infection segment, the company provides a variety of cephalosporin injections. Furthermore, Salubris is advancing novel biologics through its pipeline, including candidates like JK07 for heart failure, JK08 for solid tumors, and JK06, a biparatopic antibody-drug conjugate targeting various cancers. The firm also develops and markets medical devices, particularly for interventional cardiology and cerebrovascular applications. Established in 1998 and headquartered in Shenzhen, China, Salubris Pharmaceuticals maintains a global footprint, conducting business across China, the United States, Europe, Japan, and other international regions. Through its U.S.-based subsidiary, SalubrisBio, the company focuses on pioneering complex biologic therapeutics to address significant unmet medical needs worldwide. Recent developments include the NMPA approval of its Fu Li An combination antihypertensive drug in June 2025 and ongoing clinical advancements for its innovative biologic pipeline candidates.